Cargando…
Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target
BACKGROUND: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit from a novel therapy preventing or reversing these changes. To this end, we hav...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345230/ https://www.ncbi.nlm.nih.gov/pubmed/28283022 http://dx.doi.org/10.1186/s12885-017-3169-9 |
_version_ | 1782513675115954176 |
---|---|
author | Roberts, Cai M. Shahin, Sophia A. Loeza, Joana Dellinger, Thanh H. Williams, John C. Glackin, Carlotta A. |
author_facet | Roberts, Cai M. Shahin, Sophia A. Loeza, Joana Dellinger, Thanh H. Williams, John C. Glackin, Carlotta A. |
author_sort | Roberts, Cai M. |
collection | PubMed |
description | BACKGROUND: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit from a novel therapy preventing or reversing these changes. To this end, we have investigated the unique WR domain of the transcription factor TWIST1, which has been shown to play a role in driving metastasis and drug resistance. METHODS: In this study, we identified evolutionarily well-conserved residues within the TWIST1 WR domain and used alanine substitution to determine their role in WR domain-mediated protein binding. Co-immunoprecipitation was used to assay binding affinity between TWIST1 and the NFκB subunit p65 (RELA). Biological activity of this complex was assayed using a dual luciferase assay system in which firefly luciferase was driven by the interleukin-8 (IL-8) promoter, which is upregulated by the TWIST1-RELA complex. Finally, in order to inhibit the TWIST1-RELA interaction, we created a fusion protein comprising GFP and the WR domain. Cell fractionation and proteasome inhibition experiments were utilized to elucidate the mechanism of action of the GFP-WR fusion. RESULTS: We found that the central residues of the WR domain (W190, R191, E193) were important for TWIST1 binding to RELA, and for increased activation of the IL-8 promoter. We also found that the C-terminal 245 residues of RELA are important for TWIST1 binding and IL-8 promoter activation. Finally, we found the GFP-WR fusion protein antagonized TWIST1-RELA binding and downstream signaling. Co-expression of GFP-WR with TWIST1 and RELA led to proteasomal degradation of TWIST1, which could be inhibited by MG132 treatment. CONCLUSIONS: These data provide evidence that mutation or inhibition of the WR domain reduces TWIST1 activity, and may represent a potential therapeutic modality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3169-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5345230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53452302017-03-14 Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target Roberts, Cai M. Shahin, Sophia A. Loeza, Joana Dellinger, Thanh H. Williams, John C. Glackin, Carlotta A. BMC Cancer Research Article BACKGROUND: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit from a novel therapy preventing or reversing these changes. To this end, we have investigated the unique WR domain of the transcription factor TWIST1, which has been shown to play a role in driving metastasis and drug resistance. METHODS: In this study, we identified evolutionarily well-conserved residues within the TWIST1 WR domain and used alanine substitution to determine their role in WR domain-mediated protein binding. Co-immunoprecipitation was used to assay binding affinity between TWIST1 and the NFκB subunit p65 (RELA). Biological activity of this complex was assayed using a dual luciferase assay system in which firefly luciferase was driven by the interleukin-8 (IL-8) promoter, which is upregulated by the TWIST1-RELA complex. Finally, in order to inhibit the TWIST1-RELA interaction, we created a fusion protein comprising GFP and the WR domain. Cell fractionation and proteasome inhibition experiments were utilized to elucidate the mechanism of action of the GFP-WR fusion. RESULTS: We found that the central residues of the WR domain (W190, R191, E193) were important for TWIST1 binding to RELA, and for increased activation of the IL-8 promoter. We also found that the C-terminal 245 residues of RELA are important for TWIST1 binding and IL-8 promoter activation. Finally, we found the GFP-WR fusion protein antagonized TWIST1-RELA binding and downstream signaling. Co-expression of GFP-WR with TWIST1 and RELA led to proteasomal degradation of TWIST1, which could be inhibited by MG132 treatment. CONCLUSIONS: These data provide evidence that mutation or inhibition of the WR domain reduces TWIST1 activity, and may represent a potential therapeutic modality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3169-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-10 /pmc/articles/PMC5345230/ /pubmed/28283022 http://dx.doi.org/10.1186/s12885-017-3169-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Roberts, Cai M. Shahin, Sophia A. Loeza, Joana Dellinger, Thanh H. Williams, John C. Glackin, Carlotta A. Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target |
title | Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target |
title_full | Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target |
title_fullStr | Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target |
title_full_unstemmed | Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target |
title_short | Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST1 WR domain as a therapeutic target |
title_sort | disruption of twist1-rela binding by mutation and competitive inhibition to validate the twist1 wr domain as a therapeutic target |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345230/ https://www.ncbi.nlm.nih.gov/pubmed/28283022 http://dx.doi.org/10.1186/s12885-017-3169-9 |
work_keys_str_mv | AT robertscaim disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget AT shahinsophiaa disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget AT loezajoana disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget AT dellingerthanhh disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget AT williamsjohnc disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget AT glackincarlottaa disruptionoftwist1relabindingbymutationandcompetitiveinhibitiontovalidatethetwist1wrdomainasatherapeutictarget |